Search

Boehringer Ingelheim and Oxford BioTherapeutics Expand Collaboration to Discover Novel Selective Tumor Targets as First Bispecific Antibody Advanced into the Clinic

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

FDA Grants Fast Track to Jardiance® (empagliflozin) for CKD | Boehringer Ingelheim US

The FDA has granted Fast Track designation for JARDIANCE to reduce risk of disease progression and CV death with CKD. View ISI, PI & Med Guide.

Jardiance® (empagliflozin) Granted Designation for Heart Failure | Boehringer Ingelheim US

The FDA granted Breakthrough Therapy designation for JARDIANCE® (empagliflozin) as treatment for HFpEF. View ISI, PI and Med Guide.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fractio

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance for adults with heart failure independent of left ventricular ejection fraction

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

STIOLTO® RESPIMAT® (tiotropium bromide) Available in US | BI US

Read more about the newly available medication for COPD, STIOLTO RESPIMAT, proven to support both treatment and management of the disease.

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

New consortium EUbOPEN will provide tools to unlock disease biolog

Bringing focus to unmet needs in biliary tract and pancreatic cancer with the Brightline-2 Trial

Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced cancer in the biliary tract or pancreatic cancer.

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Innovation from within

Justine Rochon and Marc Weimer talk about the transformation of Biostatistics and Data Sciences (BDS) into a modern organisation in drug development.

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound

Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical

U.S. FDA Grants Breakthrough Therapy Designation for Spesolimab for the Prevention of Flares in Adults with Generalized Pustular Psoriasis (GPP)

Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

Boehringer Ingelheim Acquires AMAL Therapeutics

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers